Julianna LeMieux, PhD, Senior Science Writer at Genetic Engineering & Biotechnology News, interviewed our CEO Dan Mandell, PhD, and describes how non-standard amino acids (NSAAs) enable a new class of groundbreaking drugs. The article explains how our ProGly™ therapeutics use glycosylated NSAAs to direct the immune response to a protein. Julianna illustrates how antigen-specific tolerization with ProGly provides for breakthrough therapies for autoimmune disease, and new approaches to eliminating antidrug antibodies that currently prevent broader patient access to protein and gene therapies.
Learn more about our science, platform, and recent company progress by reading the full article.
